GLP-1 & Incretin Science

What the SUSTAIN Programme Data Showed

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Vilsbøll and colleagues evaluated diabetic retinopathy data from across the SUSTAIN clinical trial programme, published in Diabetes, Obesity and Metabolism in 2018 under a title linking the reduction in glycated haemoglobin to retinopathy risk.

Key facts

Analysis
Vilsbøll 2018 (PMID 29178519)
Journal
Diabetes Obes Metab, April 2018
Source data
SUSTAIN clinical trial programme
Title frames risk via
Reduction in glycated haemoglobin
Later review
Marchand 2021, Diabet Med (PMID 32799379)
Recent overview
Vujosevic 2025 (PMID 40586870)

Why a retinopathy signal was examined at all

Diabetic retinopathy is among the most consequential microvascular complications of diabetes, so any signal in a large trial programme of a diabetes medicine warrants dedicated analysis. Pooling across a programme rather than reporting one trial gives enough events to describe the pattern rather than count a handful.

What the paper's title is doing

It reads semaglutide, reduction in glycated haemoglobin, and the risk of diabetic retinopathy. That places the HbA1c reduction between the compound and the outcome, framing the question as whether the risk follows from the glycaemic improvement rather than from the drug acting on the eye. Titles are chosen carefully, and this one states a hypothesis.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Why that framing is biologically motivated

Rapid improvement in glycaemic control has long been associated with transient worsening of retinopathy, observed across intensive-control studies well before any incretin existed. A compound that lowers HbA1c substantially and quickly would be expected to encounter that phenomenon, and encountering it would say nothing specific about the compound.

Why the distinction matters clinically

If the association follows from the speed and magnitude of glycaemic improvement, then it is a known property of treating hyperglycaemia effectively rather than a property of one drug. It is managed by awareness and monitoring in those at risk, and it does not transfer as an argument against the class.

What the later literature added

Marchand and colleagues reviewed GLP-1 receptor agonists and long-term complications with a focus on retinopathy in Diabetic Medicine in 2021. Vujosevic and colleagues published on new generation glycaemic agents and retinopathy progression in Acta Diabetologica in 2025, under a title ending in a question mark. An accurate signal that the question remains live.

What this concerns

Licensed medicines studied in registered trials in people with diabetes under clinical supervision. Nothing supplied on this site is semaglutide, affects glycaemic control, or has any bearing on eye health in any person.

Frequently asked questions

Did the SUSTAIN programme show a retinopathy signal?

It produced retinopathy data warranting a dedicated pooled analysis, published by Vilsbøll and colleagues in 2018.

Why does the title mention HbA1c reduction?

It places the glycaemic improvement between the drug and the outcome, framing the question as whether risk follows from that improvement rather than from the drug itself.

Is the question settled?

No. Vujosevic's 2025 overview title ends in a question mark, which accurately reflects that it remains live.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.